Antegenes

Ecuador
Pedernales, Manabí, Ecuador, 50603

Company profile

Antegenes company profile

Antegenes’ novel genetic tests assess a patient’s personal cancer risks, and include clinical recommendations for personalized cancer prevention. The tests are based on innovative polygenic risk score technology which helps to clarify a person’s genetic predispositions to cancer. It therefore allows for more accurate prevention and early detection measures – crucial in the fight with cancer. The tests are currently being used to determine the genetic risk for four cancers: breast cancer, prostate cancer, colon cancer, and skin melanoma.

Business identity

Contact email
[email protected]
Phone number
+372-5377-8141
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2018-01-01, Year

Headquarters

Postal code
50603
Country code
EC
Continent
South America

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
4
Total equity funding
$2.5M
Last funding
Seed / $1.6M / 2022-08-02
Last equity funding
Seed / $1.6M
Investors
6
Lead investors
3
Founders
1
Articles
6

Founders and investors

Founders

Peeter Padrik

Lead investors

EIT - European Institute of Innovation and TechnologyEnterprise EstoniaTimo Rein

Investors

Aare KuristEIT - European Institute of Innovation and TechnologyEnterprise EstoniaPeep VainTimo Rein